Answers are grounded in this paper and cite their sources.
Background Sarcopenia lacks a gold-standard screening method. Muscle strength, rather than mass, is increasingly viewed as its primary marker, with evidence favoring lower-extremity strength. However, its assessment usually requires bulky laboratory dynamometry, unlike the portable handgrip test, the most widely used sarcopenia screening measure for muscle strength. We investigated whether ALM/height² and gait speed in older adults with versus without sarcopenia associate more strongly with maximal upper- or lower-extremity strength (ULSmax and LLSmax, respectively), assessing lower- and upper-extremity strength with portable, field-ready, technology-assisted tools. Methods In this secondary analysis of 198 community-dwelling older adults (sarcopenic N = 17; non-sarcopenic N = 181), Spearman correlations were computed between ULSmax, LLSmax, ALM/height², and gait speed, separately for each group. Lower-limb strength was assessed using a portable, technology-assisted force-plate system (C-station with Nintendo Wii Balance Board) suitable for community-based screening. Between-group differences in correlation coefficients were assessed using a permutation test (10,000 permutations), with 95% confidence intervals for Δρ estimated via nonparametric bootstrap resampling (10,000 resamples). Results LLSmax was more strongly correlated with ALM/height² in sarcopenic (ρ = 0.79, p < 0.001) than non-sarcopenic participants (ρ = 0.56, p < 0.001), though the between-group difference was not significant (Δρ = 0.227, 95% bootstrap CI −0.14 to 0.42). Conversely, ULSmax correlated more strongly with ALM/height² in non-sarcopenic (ρ = 0.76, p < 0.001) compared with sarcopenic older adults (ρ = 0.53, p < 0.05), and this between-group difference approached but did not reach statistical significance (Δρ = −0.230, 95% bootstrap CI −0.74 to 0.08, p = 0.063). Conclusion Associations between ALM/height² and both ULSmax and LLSmax were observed in both groups. Among sarcopenic participants, ALM/height² showed a numerically greater association with LLSmax than with ULSmax, whereas the opposite pattern was observed in non-sarcopenic individuals. Gait speed was not significantly associated with any measure in the sarcopenic group. Given the small sarcopenic subgroup, this finding should be interpreted cautiously and does not establish the absence of such associations. Since none of the between-group differences in correlation coefficients reached statistical significance, these exploratory and hypothesis-generating findings should not be interpreted as evidence to support changes to current screening practice. Importantly, adequately powered studies are still needed to determine whether portable, technology-assisted lower-limb strength assessment adds diagnostic value alongside handgrip testing in community-based sarcopenia screening. Clinical trial number Not applicable
No takes yet. Share an insight, caveat, or question.
Gennaro et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: